Download Genome instability is a salient feature of carcinogenesis. In

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Helicase wikipedia , lookup

DNA replication wikipedia , lookup

DNA profiling wikipedia , lookup

DNA nanotechnology wikipedia , lookup

DNA polymerase wikipedia , lookup

Zinc finger nuclease wikipedia , lookup

DNA repair protein XRCC4 wikipedia , lookup

Microsatellite wikipedia , lookup

Homologous recombination wikipedia , lookup

United Kingdom National DNA Database wikipedia , lookup

Replisome wikipedia , lookup

DNA repair wikipedia , lookup

Helitron (biology) wikipedia , lookup

Transcript
Genome instability is a salient feature of carcinogenesis. In eukaryotes, a genome maintenance
machinery has evolved to deal with the threat of DNA damage, and multiple pathways have emerged to
repair a wide-range of lesions. Ubiquitylation is a key post-translational modification that is prevalent
around DNA damage sites and that regulates the stability and interactions of several repair proteins.
Multiple Ubiquitin ligases, such as BRCA1, RNF8, RNF168, TRIP12 and the Fanconi core complex have
emerged as key regulators of the DNA damage response and their mutations result in hereditary
diseases and cancer formation. There is much less known about which deubiquitylases (Dubs) are
involved in DNA repair. In this application, we describe a new function of a Dub (USP20) in mediating
Chk1 phosphorylation after DNA damage by stabilizing Rad17. We define the functional and physical
interactions between USP20 and Rad17 and we show that USP20 protects Rad17 from proteasomemediated degradation by deubiquitylation. We also implicate USP20 in the resistance to DNA damaging
agents and in the repair of DNA double strand breaks by homologous recombination. Finally, we reveal a
functional interaction between USP20 and the MDM2-TP53 pathway, which is an important cancer
therapy target.